Integrated Stress Response Antibody Sampler Kit #56392
Product Information
Kit Usage Information
Protocols
- 3192: Western Blotting
- 3398: Western Blotting, Fluorescent Western, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin)
- 5324: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin)
- 7074: Western Blotting
- 11815: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay, CUT&Tag
- 12297: Western Blotting, Immunoprecipitation (Agarose)
- 41222: Western Blotting
- 52933: Western Blotting, Immunoprecipitation (Agarose)
- 65981: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence
- 94668: Western Blotting, Immunofluorescence, Flow
Product Description
Background
Heme-regulated inhibitor (HRI), a heme-regulated eIF2α kinase, is a cytosolic protein kinase that is highly expressed in erythroid cells (7,8). Upon stress conditions such as heme deficiency, oxidative stress, osmotic shock, mitochondrial dysfunction, and heat shock, HRI is a key activator of the integrated stress response (ISR). Following activation, HRI is autophosphorylated, leading to eIF2α phosphorylation, which controls protein synthesis by inhibiting translational initiation (9-13).
Protein kinase R (PKR) is transcriptionally induced by interferon and activated by double-stranded RNA (dsRNA). PKR inhibits translation initiation by phosphorylating eIF2α and also controls the activation of several transcription factors, such as NF-κB, p53, and the Stats. In addition, PKR mediates apoptosis induced by various stimuli, including LPS, TNF-α, viral infection, and serum starvation (14,15).
Growth arrest and DNA damage-inducible protein (GADD34) is essential for cell stress responses. It is induced by stresses such as DNA damage and endoplasmic reticulum (ER) stress. GADD34 binds to type 1 protein phosphatase (PP1), a serine/threonine phosphatase, and promotes PP1 to dephosphorylate eIF2α (18,19). GADD34 expression is correlated with eIF2α dephosphorylation late in the stress response, suggesting a critical role for GADD34 in a negative feedback loop to reduce stress response signaling and shift cells from protein synthesis inhibition to stress-induced gene expression (20).
Activating transcription factor-4 (ATF-4), an ATF/cAMP-responsive element-binding protein family member, functions in the PERK and eIF2α ER stress-responsive pathway (21-23). ER stress represses the translation of the majority of mRNAs but selectively stimulates translation of certain mRNAs, including ATF-4 (22). Induced expression of ATF-4 increases the expression of genes critical for the recovery from ER stress (24).
- Harding, H.P. et al. (1999) Nature 397, 271-4.
- Shi, Y. et al. (1998) Mol Cell Biol 18, 7499-509.
- Harding, H.P. et al. (2000) Mol Cell 5, 897-904.
- Kaufman, R.J. (1999) Genes Dev 13, 1211-33.
- Sheikh, M.S. and Fornace, A.J. (1999) Oncogene 18, 6121-8.
- Deng, J. et al. (2002) Curr Biol 12, 1279-86.
- Fagard, R. and London, I.M. (1981) Proc Natl Acad Sci USA 78, 866-70.
- Chefalo, P.J. et al. (1998) Eur J Biochem 258, 820-30.
- Lu, L. et al. (2001) Mol Cell Biol 21, 7971-80.
- McEwen, E. et al. (2005) J Biol Chem 280, 16925-33.
- Igarashi, J. et al. (2011) FEBS J 278, 918-28.
- Guo, X. et al. (2020) Nature 579, 427-432.
- Chakrabarty, Y. et al. (2024) Mol Cell 84, 1090-1100.e6.
- Williams, B.R. (1999) Oncogene 18, 6112-20.
- Gil, J. and Esteban, M. (2000) Apoptosis 5, 107-14.
- Kimball, S.R. (1999) Int J Biochem Cell Biol 31, 25-9.
- de Haro, C. et al. (1996) FASEB J 10, 1378-87.
- Novoa, I. et al. (2001) J Cell Biol 153, 1011-22.
- Brush, M.H. et al. (2003) Mol Cell Biol 23, 1292-303.
- Novoa, I. et al. (2003) EMBO J 22, 1180-7.
- Fawcett, T.W. et al. (1999) Biochem J 339 (Pt 1), 135-41.
- Harding, H.P. et al. (2000) Mol Cell 6, 1099-108.
- van Huizen, R. et al. (2003) J Biol Chem 278, 15558-64.
- Yusta, B. et al. (2006) Cell Metab 4, 391-406.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.